• Overview
  • Details
  • More
Share Products Categories Channel Cart

1/6
Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System图1Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System图2Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System图3Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System图4Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System图5Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System图6

Real Time Continuous Glucose Monitoring Solutions Cgm Sensor Glucose Monitoring System

Price $39.00
Min Order 100 Pieces  
Shipping from Shandong, China
Quantity
-+
Product details
CT3
Physiological Functions of Diagnosis and Monitoring Equipment
Blood Glucose Meter
CE, ISO13485
Middle-aged and Old
100sets
OEM as customer
Carton
China
Product Description
Product Description

Real Time Continuous Glucose Monitoring Solutions CGM Sensor Glucose Monitoring System

The durable and high-precision  AnytimeCT3 CGMS is a system for blood glucose monitoring. It helps patients understand their glucose changes in order to effectively manage their blood glucose levels. The system enables continuous 24-hour glucose monitoring over a span of 14 days, generating a glucose value every 3 minutes. The advanced technology makes it possible to capture masses of reliable data and filter out interfering signals. An associated app provides early warnings and professional treatment advice.



 

SMARTER

 

  • 7 glucose trend arrows
  • 4 options of glucose timeline
  • Statistics and Daily Report can be outputed
  • Share real-time data with up to 20 people
  • Allow logging of meals, exercise, and insulin

EFFICIENT

 

  • Real-time High and Low alerts to take action
  • Can help reduce HbA1c
  • Can help reduce Hhypoglycemic Events

RELIABLE

 

  • The clinical trial for the CT3 continuous glucose monitoring system was just completed in 2022, involving 72 patients in three top-level hospitals in China. An overall MARD (vs venous blood)of 9.07%, and the consensus error grid of 99.95%, were achieved.
 
 

Buyer review
Loading review details...
Contact

Qingdao Hiprove Medical Technologies Co., Ltd.

Audited Supplier10 Years
ProfileCertified by SGS/BV

Message Type

* Content

* Name

* Phone

* Email

* Captcha

captcha

Recommended for you